

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:

January 17, 2000

Date


Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran

Serial No.: 09/351,149

Filed: July 12, 1999

For: CANCER TREATMENT KITS
COMPRISING THERAPEUTIC
CONJUGATES THAT BIND TO
AMINOPHOSPHOLIPIDS

Group Art Unit: 1623

Examiner: Unknown

Atty. Dkt. No.: 4001.002383

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).


In accordance with 37 C.F.R. § 1.98 (a)(3), a concise explanation of the relevance of the foreign language document submitted (PCT Application No. WO 98/29453), as it is presently understood, is supplied herewith. The statement submitted takes the form of an attachment to this document, which was obtained from Derwent's World Patent Index, as presented in file 351 on the Dialog Information System. Applicants' submission of this information alone is motivated solely by the high cost of obtaining a translation of the full length document, and should in no way be interpreted as a failure to comply with the duty of disclosure or an intent to deceive the Examiner.

In accordance with 37 C.F.R. § 1.97(e)(1), Applicants hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the present statement, as evidenced by the date of the enclosed search report.

In any event, the present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials,

the Assistant Commissioner is hereby authorized to deduct said fees from Williams, Morgan & Amerson, P.C., Deposit Account No. 50-0786/4001.002383.

Respectfully submitted,



Shelley P.M. Fussey
Reg. No. 39,458
Agent for Applicants

WILLIAMS, MORGAN & AMERSON
7676 Hillmont, Suite 250
Houston, Texas 77040
(713) 934-7000

Date: January 17, 2000

DIALOG(R) File 351:DERWENT WPI
(c) 2000 DERWENT INFO LTD. All rts. reserv.

011971141

WPI Acc No: 98-388051/199833

Drugs containing peptide(s) with specific affinity to phospholipid(s) -
such as phosphatidyl serine, for treatment of blood coagulation,
inflammatory and immunological disorders

Patent Assignee: MOCHIDA PHARM CO LTD (MOCH)

Inventor: HASEGAWA T; KURIYAMA S

Number of Countries: 021 Number of Patents: 001

Patent Family:

| Patent No | Kind | Date | Applicat No | Kind | Date | Main IPC | Week |
|-----------|------|------|-------------|------|------|----------|------|
|-----------|------|------|-------------|------|------|----------|------|

| | | | | | | | |
|------------|----|----------|----------|---|----------|-------------|--------|
| WO 9829453 | A1 | 19980709 | WO 98JP2 | A | 19980105 | C07K-019/00 | 199833 |
|------------|----|----------|----------|---|----------|-------------|--------|

JAN 24 2000

Priority Applications (No Type Date): JP 96359053 A 19961227

Patent Details:

| Patent | Kind | Lan | Pg | Filing Notes | Application | Patent |
|--------|------|-----|----|--------------|-------------|--------|
|--------|------|-----|----|--------------|-------------|--------|

| | | | | | | |
|------------|----|---|-----|--|--|--|
| WO 9829453 | A1 | J | 117 | | | |
|------------|----|---|-----|--|--|--|

Designated States (National): CA JP KR US

Designated States (Regional): AT BE CH DE DK ES FI FR GB GR IE IT LU MC

NL PT SE

Abstract (Basic): WO 9829453 A

Drug compositions contain as active component a peptide which has specific affinity to particular phospholipids (such as phosphatidyl ethanolamine or phosphatidyl serine), especially to phospholipids which constitute a lipid bilayer of cellular cortex and of which the concentration in the bilayer increases in cells which are abnormal (e.g. through injury, denaturation or activation).

In particular, the peptide contains a sequence having phospholipid affinity and a structure of formula (I).

(A1)a-(A2)b-(A3)c (I)

(A1) is one of two specific (130 and 30 amino acid) sequences given in the specification;

(A2) and (A3) are TRYLRIHQPQSWVHQIALR (II), LRYLRIHQPQSWVHQIALR or MEVLGCEAQNLY (III);

a = 0-5;

b = 1-5, and

c = 0-5.

Preferred are the formulae A1-A2-A3, A2-A3, A2-A2-A3, A2-A2-A2-A3 or A2-A2 (especially A2-A2-A3, A2-A2-A2-A3 or A2-A2).

The sequence is linked to a peptide such as a blood factor, especially thrombo-modulin, urina-statin or membrane cofactor protein.

Also claimed are:

(1) peptides of sequence (I), and

(2) DNAs encoding these peptides or encoding peptides with phospholipid affinity which incorporate them as part of the sequence.

USE - The drugs are used for the treatment and prevention of diseases involving blood coagulation, inflammatory and immunological disorders.

Dwg.0/22

Derwent Class: B04; D16

International Patent Class (Main): C07K-019/00

International Patent Class (Additional): A61K-047/48; C07K-014/745;

C12N-015/12; C12P-021/02; C12R-001-91